The big business behind weight-loss drugs: Global market to hit $150 billion by 2035

They burst onto the scene 4 years in the past and are taking up the pharmaceutical world. New GLP-1-based medicine like Ozempic, Wegovy or Zepbound are stated to be a weight-loss recreation changer and will drive large pharma’s income for years to return. However they arrive with a hefty price ticket, whereas some 50 to 70 p.c of individuals taking GLP-1s undergo unintended effects. Charles Pellegrin asks Frederic Bizard, a well being economist and professor at ESCP Enterprise College, who has essentially the most to achieve from this pharma revolution.



Source link